Published in Pharmacol Rep on January 18, 2010
Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep (2008) 0.83
Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep (2005) 0.83
Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep (2006) 0.80
Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol (2004) 0.79
Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol (2005) 0.79
Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Pol J Pharmacol (2003) 0.78
Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep (2009) 0.77
Effect of co-administration of fluoxetine and amantadine on immunoendocrine parameters in rats subjected to a forced swimming test. Pharmacol Rep (2010) 0.77
Effect of repeated co-treatment with imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and alpha 1-adrenergic systems in rats. Pharmacol Rep (2007) 0.76
Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep (2009) 0.76
Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol (2005) 0.75
Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats. Pharmacol Rep (2009) 0.75